PolyActiva reports promising clinical trial results for its 6-month sustained drug delivery, biodegradable ocular implant in glaucoma patients.
The interim Phase 2a results demonstrate a sustained >20% reduction of IOP after 6 months with a favorable safety profile.
PolyActiva presents positive clinical trial results at the 2022 American Glaucoma Society Annual Meeting – March 2022
PolyActiva announces positive Phase IIa results in glaucoma trial with low dose cohort.
PolyActiva successfully completes initial clinical trial with Latanoprost FA SR Ocular Implant delivering glaucoma treatment to patients over a six-month period.
PolyActiva appoints Tracy Valorie, ophthalmic industry expert and former Bausch + Lomb executive, to its Board of Directors.
PolyActiva completes recruitment in key Phase I glaucoma implant safety study. Six-month treatment period demonstrated.
© 2023 PolyActiva. All Rights Reserved. Caution: PolyActiva products are not for sale in the US